OPENING SHOT
The Impairment Is the Confession.
Coloplast took a DKK 3.00 billion goodwill write-down on Kerecis this week and hit a 52-week low. ConvaTec reported four-month organic growth that missed consensus, with InnovaMatrix dragging group revenue by 300 basis points — and explicitly flagged "high market uncertainty" on the segment going forward. Two acquisitions. Two companies. One shared variable: they both bought into the outpatient skin substitute channel at scale, right before the January 1 reset made that thesis structurally untenable.
The impairments and guidance haircuts are not surprises at this point. They are the accounting formalization of what the market has been pricing in for months. What matters now is what sits beneath them.
BioStem Technologies reported this week that 87% of its Q1 revenue came from the hospital channel, the direct result of a channel pivot completed in a single quarter. Mölnlycke announced a majority-owned joint venture in China this morning, combining its wound care portfolio with Zhende Medical's nationwide reach across 10,000 hospitals and 200,000 pharmacies. PlasmaCure's PLASOMA cold plasma device posted 2.5x wound closure rates versus standard of care in a peer-reviewed RCT and is now building its U.S. regulatory entry case.
The companies absorbing impairments built the right products and bought into the wrong channel at the wrong time. The companies reporting momentum built for hospital, surgical, and international growth — and positioned before the reset created the white space.
The sorting is not coming. It's here.
BTK INNOVATION INDEX REPORT — 283 COMPANIES. ONE INDEPENDENT SCORE.
Every company indexed - Innovation Velocity, Clinical Evidence, Technical Differentiation, Regulatory & Reimbursement, Strategic & Commercial Activity, Brand & Market Signal - scored on merit.
The Q1 earnings cycle has become a real-time validation exercise. The companies that indexed well before the reset are the ones reporting structural repositioning toward hospital, ASC, and surgical channels. Others are reporting impairments. We give you the insights to see this before it happens.
→ Access the 2026 BTK Innovation Index at belowtheknee.co/innovation-index
You haven’t seen a market report like this before
WOUND CARE
Earnings | ConvaTec: InnovaMatrix Drags Group Growth; Shares Fall 7%
ConvaTec reported four-month organic revenue growth of 1.6% including InnovaMatrix, well below the Visible Alpha consensus of 2.8% for the first half of 2026. Excluding InnovaMatrix, growth came in at 4.8%. Shares fell over 7% on the report.
InnovaMatrix represented a 300-basis-point headwind to group organic growth for the period, attributed directly to structural changes in the U.S. skin substitute market. The company now estimates approximately $20 million in InnovaMatrix revenue for full-year 2026 and acknowledged that market uncertainty remains high. Full-year 2026 guidance was left unchanged at 5–7% organic revenue growth excluding InnovaMatrix, with adjusted operating profit margin of at least 23% and double-digit growth in adjusted EPS, but growth is expected to be weighted toward the second half.
The rest of the ConvaTec business held up. Ostomy Care and Continence Care both grew at a mid-single-digit rate roughly in line with consensus. Advanced Wound Care grew at a mid-single-digit rate excluding InnovaMatrix - beating a consensus expectation that had embedded a significant InnovaMatrix decline. Morningstar maintained its narrow-moat rating and reiterated shares remain undervalued following the update, with a fair value estimate of GBX 221 against a trading price around GBX 214.
The BTK read: InnovaMatrix is doing to ConvaTec what Kerecis has done to Coloplast - a skin substitute acquisition that ran directly into the January 1 reset. Both companies acquired growth-stage wound care assets at elevated valuations in a pre-reset market environment. Both are now carrying explicit guidance haircuts that quantify the cost. The difference: ConvaTec's core business is more diversified, and the Morningstar undervalued assessment reflects that the chronic care engine can continue performing even as InnovaMatrix stabilizes. The question going forward is whether $20M represents a floor or a ceiling, and whether "high market uncertainty" is an 18-month statement or a multi-year one.
Commercial | Coloplast: DKK 3B Impairment, 52-Week Low (Kerecis Thesis Under Pressure)
The Coloplast slide continued this week. Shares hit a 52-week low of DKK 390.10, down roughly 27% year to date. The company has now taken a DKK 3.00 billion goodwill impairment on its Kerecis acquisition, formally recognizing that the thesis underpinning the $1.3 billion deal has been materially impaired by the January 1 Medicare reimbursement reset.
Full-year FY25/26 guidance stands at 5–6% organic growth and roughly 5% EBIT growth in constant currencies, down from prior expectations. Analyst consensus sits at "Hold" across approximately 20 covering analysts, with an average target of DKK 464.90 - implying potential upside from current levels but reflecting a reset in growth expectations across the board. Core franchises remain intact: Ostomy Care grew 7% organically in Q2, Continence Care 8%. The chronic care engine is not broken. New CEO Gavin Wood took the helm May 1, arriving with direct MedTech and wound care experience at a moment that demands exactly that.
The BTK read: The impairment converts what has been an earnings guidance story into a balance sheet story. The DKK 3B write-down is Coloplast formally acknowledging that the outpatient skin substitute growth thesis - the entire strategic rationale for the Kerecis acquisition - cannot be carried at original value given the current reimbursement environment. The inpatient Kerecis business is intact and growing double-digits. Recovery depends on whether the outpatient market normalizes, or whether this impairment is the first chapter of a longer recalibration. New leadership, new chapter. The question is which story they write from here.
Earnings | BioStem Technologies Q1: Hospital Pivot Complete, 87% of Revenue Now Hospital-Sourced
BioStem Technologies completed its acquisition of BioTissue's surgical and wound care assets in late January and spent Q1 executing the channel pivot. Q1 revenue of $6.1M came in above the prior guidance range of $5–6M, with hospital revenue at $5.4M (87% of total) and a 61% gross margin. The physician office business contributed $0.8M, reflecting expected disruption in that channel under the current reimbursement environment.
The acquisition added perinatal tissue allografts, an experienced sales organization, GPO contract access, and a direct hospital customer base. The company expanded its direct sales force from 18 to 35 representatives and reassigned all GPO contracts. Full-year 2026 guidance was initiated at $25–29M, with sequential growth expected as the integrated hospital-focused commercial platform ramps. The company also advanced audited financials for 2024 and 2025 and is progressing toward a planned Nasdaq uplisting.
The BTK read: BioStem is one of the clearest execution stories on the channel migration thesis this earnings cycle. Physician office revenue disruption is fully expected, that channel is under sustained structural pressure. Hospital revenue at $5.4M with 87% share in the first post-acquisition quarter reflects genuine commercial integration speed. If full-year guidance of $25–29M is achievable, the operational leverage in the hospital-focused model becomes visible by Q3. Watch the Nasdaq uplisting progression - it's a capital markets signal that matters for this company's next stage.
Commercial | MTF Biologics + New Horizon Medical Solutions: Post-Acute Distribution Built for the Reset Environment
MTF Biologics, the global nonprofit tissue bank, named New Horizon Medical Solutions (NHMS) as exclusive distributor of AmnioBand® Membrane for the post-acute and outpatient markets - targeting wound care specialists, podiatrists, and mobile care practitioners across the United States. The agreement pairs AmnioBand's Level 1 peer-reviewed clinical evidence base with NHMS's specialized provider network and hands-on field support.
The timing and channel targeting are deliberate. AmnioBand Membrane is one of only 18 tissues confirmed covered under the updated January 1, 2026 Medicare LCDs for skin substitute grafts, maintaining coverage for DFUs and VLUs, and is one of only five tissues covered for both indications. NHMS is not a generalist distributor: the company supplies amniotic and placental tissue allografts, offers full revenue-cycle and billing services, EHR/inventory integrations, and reimbursement support specifically for outpatient, surgical, and wound care providers. The combination is a purpose-built model for the post-reset distribution environment.
The BTK read: This is what market infrastructure reformation looks like in practice. The January 1 reset didn't eliminate the post-acute and outpatient wound care market, it eliminated the reimbursement arbitrage that was distorting it. What's being built in its place is a distribution model based on three things: covered products, Level 1 clinical evidence, and specialized provider support that can actually navigate the new billing and documentation requirements. AmnioBand is one of the few CTP products that cleared the LCD filter with both DFU and VLU coverage intact. NHMS is one of the few distributors built specifically for the post-acute and mobile care channels where volume is migrating. The fit is intentional, and it's the right structure for what comes next.
Commercial | Mölnlycke + Zhende Medical: A China JV Built for the Next Decade
Mölnlycke Health Care and Zhende Medical announced the formation of a majority-owned Mölnlycke joint venture in China today — Mölnlycke Zhende (Shanghai) Medical Technology Co Ltd. The JV combines Mölnlycke's advanced wound care portfolio, including its proprietary Safetac® technology, with Zhende Medical's assets including an epidermal cell separator and solutions for burns, vitiligo, and chronic wound care.
The combined commercial footprint spans nearly 10,000 hospitals, 200,000 pharmacies, and eCommerce infrastructure across China. Majority-owned by Mölnlycke and headquartered in Shanghai, it is expected to be operational in Q3 2026, initially focused on sales and distribution with potential for co-development over time. China's advanced wound dressing segment is valued at approximately EUR 380 million and growing, driven by chronic-disease prevalence and aging demographics.
The BTK read: While the U.S. outpatient market resets, Mölnlycke is deploying capital and commercial infrastructure into high-growth international markets with significant unmet need. China is the single largest addressable growth opportunity in advanced wound care globally. This JV structure; majority-owned Mölnlycke, local partner distribution and clinical depth is the right model for the market. This is a long-horizon strategic move, announced on a day when most of the sector is focused on impairments. The contrast is instructive.
AI & INNOVATION | Wound Photography Has a Color Problem — And It's Measurable
A peer-reviewed literature review published in Wounds (April 2026, 38(4):90-96) makes a pointed and well-documented case: wound photography, the clinical modality that underlies documentation, telemedicine, reimbursement adjudication, and AI model training, has no objective accuracy standard, and the data shows it needs one.
Across studies reviewed, uncalibrated wound photographs showed substantial color deviation from known reference values. In large real-world datasets of over 50,000 wound photographs, a single clinically relevant reference color was reproduced as tens of thousands of distinct and erroneous values across uncalibrated images. The colors most affected — red, yellow, and black tissue ranges — are precisely the ones clinicians rely on to distinguish granulation tissue, slough, inflammation, ischemia, and necrosis. The clinical and commercial implications extend beyond documentation: analytic studies showed AI predictive performance for wound healing varied directly with baseline image fidelity, with gains of up to 12% in model discrimination as color accuracy improved.
The core thesis is correct. Objective color calibration in wound photography is not a nice-to-have; it is foundational infrastructure for reliable AI performance, defensible documentation, and payer adjudication. The field should be moving toward an accuracy standard, and papers like this one are a necessary part of getting there.
That said, the editorial independence flag here is real and worth naming. One of the lead authors is the founder of a company with a direct commercial interest in a color calibration solution — and that conflict is disclosed, but only in a footnote. The paper's conclusion points in the direction of a specific calibration approach rather than toward an open standard. In a market that is actively building AI-driven imaging and documentation infrastructure, that distinction matters: the right answer is not one proprietary calibration product — it is an objective, reproducible standard that any system can meet.
There is also a technical concern worth raising for developers and procurement teams evaluating imaging platforms. If a wound imaging system relies on a physical fiducial — a color reference target placed in the photographic field — that target itself must be a manufactured, controlled, and certified item with defined colorimetric tolerances. A printed reference card is subject to the same ink variation, substrate inconsistency, and aging degradation that distorts the wound images it is meant to correct. A calibration tool that cannot itself be verified against a known standard introduces the exact class of error it is intended to eliminate. Any system claiming color accuracy through a fiducial should be able to answer: who manufactured it, to what tolerance, and how is that tolerance maintained over time.
The BTK read: The problem this paper identifies is real and consequential. The solution space it points toward is narrower than the problem demands. For AI platform developers, imaging system designers, and health systems building wound care documentation workflows, the right frame is: what is the minimum reproducible standard for color fidelity in wound photography, and how do we certify that any compliant system meets it — regardless of vendor? That is the standard the market needs. A single commercially-interested solution is not it.
Science | Light-Controlled Microrobots: Early-Stage Science With Real Long-Term Implications
Published in Science Advances this week: researchers developed a system using blue and red light to remotely assemble and disperse swarms of biohybrid microrobots for targeted drug delivery in wounds. The robots combine living green microalgae with PLGA nanoparticles loaded with medicine. An AI program scanned simulated wound geometry and projected light patterns to guide the robots to deliver drug payloads directly to the target area.
The BTK read: Early-stage academic science, not near-term commercial development. But the directional thesis matters: AI-guided, light-controlled, biocompatible delivery systems that match drug placement to wound geometry represent the kind of precision architecture that next-generation wound care models will eventually require. The clinical translation timeline is long. The intellectual trajectory is worth tracking.
CLINICAL | PlasmaCure PLASOMA: Cold Plasma Builds the U.S. Entry Case
New clinical data on PlasmaCure's PLASOMA device was highlighted this week. A peer-reviewed RCT showed PLASOMA achieving wound closure in 62% of treated wounds within the specified time versus 25% with standard care — 2.5 times more effective. The device is CE-marked, Class IIb, and generates cold plasma directly on the wound surface via a 2-minute treatment session compatible with both clinic and home use.
PlasmaCure secured a €6M investment in 2025 with U.S.-focused financing through Venture Medical, which will lead the FDA clearance process and serve as the exclusive U.S. commercialization partner. IP protection spans the U.S., EU, UK, and China.
The BTK read: PLASOMA is a credible non-tissue, non-human-allograft modality entering a market actively seeking validated alternatives to skin substitutes. The 2.5x closure rate in a legitimate RCT is not a marketing claim — it's a peer-reviewed endpoint that supports a coverage argument. The FDA path, U.S. distribution infrastructure, and RCT foundation put PLASOMA in a credible pre-commercialization position. One to watch closely in the innovation layer of the market.
HEALTH SYSTEM | AI and Remote Monitoring Scale Into Chronic Disease Infrastructure
Modern Healthcare reported this week that health systems including CenterWell, Rush, and DaVita are investing in AI and remote patient monitoring to address chronic disease — covering diabetes, kidney disease, hypertension, and the comorbidity clusters that drive wound care demand at the population level.
The BTK read: This is the upstream signal. The chronic disease management infrastructure being built by major health systems directly determines the patient population that eventually presents with diabetic foot ulcers, venous leg ulcers, and pressure injuries. The investment in AI monitoring at this level will produce measurable downstream effects in wound care utilization over the next 3–5 years. It's not a wound care story yet — but it will be.
FINANCE & MARKET
Q1 2026: The Channel Shift Thesis Is Now in the Earnings Record
The Q1 2026 earnings cycle has now formally confirmed the pattern BTK has been tracking since January: companies built for the hospital, ASC, and surgical channel are outperforming; companies with outpatient skin substitute exposure are absorbing the structural damage.
BioStem Technologies (OTC: BSEM) — Revenue $6.1M, 87% hospital-sourced. Full-year guidance $25–29M. Channel pivot from physician office to hospital completed via BioTissue assets acquisition. Nasdaq uplisting in progress.
ConvaTec (LSE: CTEC) — Four-month organic growth 1.6% including InnovaMatrix, 4.8% excluding. Shares fell 7%. InnovaMatrix ~$20M full-year revenue estimate with high uncertainty acknowledged. Full-year guidance unchanged at 5–7% excluding InnovaMatrix. Morningstar: narrow moat maintained, shares undervalued.
Coloplast (CPH: COLOB) — DKK 3.00B goodwill impairment on Kerecis. Shares at 52-week low, down ~27% YTD. FY25/26 guidance: 5–6% organic growth. Core chronic care franchises (Ostomy +7%, Continence +8%) intact; outpatient skin substitute channel structurally impaired.
Earlier in the cycle: BioStem, Sanara MedTech, AVITA Medical, and Integra LifeSciences all reported Q1 results consistent with the same thesis — hospital and ASC channel positioning is now the core commercial argument, and companies with surgical franchise strength are outperforming those with outpatient exposure.
The BTK read: The sorting is happening in real time. The Index called it before the earnings. The earnings are confirming it.
A WORD ON THIS WEEKEND
This edition goes out on the Friday of Memorial Day weekend in the United States.
For those of us who wore the uniform, this weekend carries a meaning that is different from Veterans Day. Memorial Day is not a celebration of those who served. It is a remembrance of those who did not come home.
Enjoy the long weekend. Spend time with the people you care about. Go to the beach, have fun - but take a moment — just a moment — to think about the ones who made can’t.
— Scott
From my last visit to Arlington National
📅 UPCOMING EVENTS
May 26–29 | New Orleans, LA 🔥 New Cardiovascular Horizons (NCVH) — The Roosevelt New Orleans The 27th annual NCVH conference. PAD, critical limb ischemia, amputation prevention, and endovascular intervention. Includes the CLI Summit — the nation's longest-running dedicated CLI and limb salvage educational program.
May 31–June 2 | WOCNext 2026 WOCN Society annual clinical gathering. Strong nursing and advanced practice track.
June 21 | St. Louis, MO St. Louis Wound & Vascular Symposium — Hilton Frontenac
August 6–9 | Nashville, TN 🔥 APMA Annual Scientific Meeting (The National) — Gaylord Opryland The national gathering for podiatric medicine. Four full days.
September 10–11 | New Orleans, LA 🔥 IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton Three tracks: tissue repair, post-acute and mobile wound care, CAMPs market dynamics.
September 14–16 | Louisville, KY 🔥 NAWCO HEAL Conference 2026 The National Alliance of Wound Care and Ostomy's annual conference. Clinical, regulatory, and reimbursement tracks across wound, ostomy, and continence.
September 23–27 | Kuala Lumpur, Malaysia 🔥 World Union of Wound Healing Societies (WUWHS) 2026 The quadrennial global congress of the wound healing community.
October 15–18 | Las Vegas, NV 🔥 SAWC Fall 2026 — Caesars Palace Co-located with NPIAP Fall Conference. New Mobile Wound Care Track for 2026.
October 22–24 | Anaheim, CA 🔥 DFCon 2026 — JW Marriott Anaheim Resort ALPS's global interdisciplinary diabetic foot conference.
November 6 | Virtual WoundCon Fall 2026
December 9–12 | Phoenix, AZ Desert Foot Multi-Disciplinary Limb Salvage & Wound Care Conference — Sheraton Phoenix Downtown
Below The Knee | belowtheknee.co Independent market intelligence for wound care, limb salvage, vascular intervention, and foot & ankle.
Not subscribed? → newsletter.belowtheknee.co Forward this to one person in your network who works in this space.
See you next week. — Scott